@article{a4f82ccfb9e74a3dab596a0c8cf585a0,
title = "Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations",
abstract = "Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We reviewed the database of the MD Anderson Cancer Center and identified metastatic LUSC with classic EGFR or ALK alterations. Results: There were eight patients with EGFR-mutant LUSC (median age = 58 y) and six patients with EML4-ALK LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified. Of the 14 patients, 11 (79%) were females and 12 (86%) were never smokers, similar to the demographics of EGFR or ALK LUAD. With TKI treatment, seven of eight cases of EGFR LUSC and four of six cases of ALK LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for EGFR-mutant and ALK-rearranged LUSC, respectively. In addition, we compared comutation profile of EGFR-mutant LUAD (The Cancer Genome Atlas, n = 46) versus LUSC (n = 19) and found that the comutation patterns are more consistent with squamous disease with a higher incidence of PIK3CA (p = 0.02) and KRAS or BRAF (p = 0.04) alterations. Conclusions: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.",
keywords = "ALK, EGFR, Lung squamous cell carcinoma, Targeted therapy, Tyrosine kinase inhibitor",
author = "Lewis, {Whitney E.} and Lingzhi Hong and Mott, {Frank E.} and George Simon and Wu, {Carol C.} and Waree Rinsurongkawong and Lee, {J. Jack} and Lam, {Vincent K.} and Heymach, {John V.} and Jianjun Zhang and Xiuning Le",
note = "Funding Information: Disclosure: Dr. Lam reports receiving personal fees from Takeda, Seattle Genetics, Bristol-Myers Squibb, AstraZeneca, and Guardant Health and research funding from Seattle Genetics, Bristol-Myers Squibb, GlaxoSmithKline, and Merck, all outside of the submitted work. Dr. Heymach reports receiving advisory/consulting fees from AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, Sanofi, Takeda Pharmaceuticals, Mirati Therapeutics, Bristol-Myers Squibb, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Leads Biolabs, and RefleXion, and research funding from GlaxoSmithKline, AstraZeneca, and Spectrum, all outside of the submitted work. Dr. Zhang reports receiving personal fees from Bristol-Myers Squibb, AZ, Novartis, Johnson and Johnson, GenePlus, and Innovent, and research funding from Merck, Novartis, and Johnson and Johnson, all outside the submitted work. Dr. Le reports receiving consultant and advisory fees from Eli Lilly, AstraZeneca, EMD Serono, Daiichi Sankyo, Spectrum Therapeutics, Boehringer Ingelheim, Hengrui Therapeutics, and Novartis, and research funding from Eli Lilly and Boehringer Ingelheim, all outside of the submitted work. The remaining authors declare no conflict of interest.The authors acknowledge the generous philanthropic contributions to the University of Texas MD Anderson Cancer Center Moon Shots Program, MD Anderson Cancer Center Support Grant P30 CA01667. The authors thank the GEMINI team for their research support. Funding Information: Disclosure: Dr. Lam reports receiving personal fees from Takeda , Seattle Genetics , Bristol-Myers Squibb , AstraZeneca , and Guardant Health and research funding from Seattle Genetics , Bristol-Myers Squibb, GlaxoSmithKline , and Merck , all outside of the submitted work. Dr. Heymach reports receiving advisory/consulting fees from AstraZeneca, Boehringer Ingelheim , Catalyst, Genentech , GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum , Sanofi , Takeda Pharmaceuticals, Mirati Therapeutics, Bristol-Myers Squibb, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono , Pneuma Respiratory, Kairos Venture Investments, Leads Biolabs, and RefleXion, and research funding from GlaxoSmithKline, AstraZeneca, and Spectrum , all outside of the submitted work. Dr. Zhang reports receiving personal fees from Bristol-Myers Squibb, AZ , Novartis , Johnson and Johnson , GenePlus, and Innovent, and research funding from Merck, Novartis, and Johnson and Johnson, all outside the submitted work. Dr. Le reports receiving consultant and advisory fees from Eli Lilly, AstraZeneca, EMD Serono, Daiichi Sankyo, Spectrum Therapeutics, Boehringer Ingelheim, Hengrui Therapeutics, and Novartis, and research funding from Eli Lilly and Boehringer Ingelheim, all outside of the submitted work. The remaining authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2020 The Author(s)",
year = "2021",
month = nov,
doi = "10.1016/j.jtocrr.2021.100237",
language = "English (US)",
volume = "2",
journal = "JTO Clinical and Research Reports",
issn = "2666-3643",
publisher = "Elsevier Inc.",
number = "11",
}